Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of EHP-101 in healthy subjects
NCT03745001Phase 1Completed
- Sponsor
- Emerald Health Pharmaceuticals Inc.
- Start
- Sep 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of etrinabdione in systemic sclerosis (SSc) and multiple sclerosis (MS) (4 arms), sponsored by Emerald Health Pharmaceuticals Inc. Primary endpoint: Treatment emergent adverse events at 30 days. Started Sep 2018; status: completed.
02
Drugs
etrinabdione
03
Conditions
systemic sclerosis (SSc)multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03745001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03745001.